GOVX-B11: Ph I HVTN 114 started

GeoVax said the HIV Vaccine Trials Network (HVTN) began the double-blind, placebo-controlled, U.S. Phase I HVTN 114 trial to evaluate the company's intramuscular GOVX-B11 with or without AIDSVAX B/E v...